Palo Alto Networks Inc (PANW) Stock Price Today
Aura AI Summary
Key Stats
- $259.99BMarket Cap
- -Volume
- TechnologySector
- $358.6852W High
- $141.6752W Low
- -Typical Hold Time
- $258.95BEnterprise Value
- -Div Yield
- -Trading Activity
Track Palo Alto Networks Inc (PANW) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Palo Alto Networks Inc has traded between a low of $141.67 and a high of $358.68, highlighting its annual price range. Buy and sell Palo Alto Networks Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Most Recent News
Meta in talks to lease $10B AI compute to Anthropic, opening new revenue amid heavy AI investments
Meta, led by Mark Zuckerberg, is in early discussions to lease $10 billion worth of AI computing power to Anthropic. This deal could create a significant new revenue stream for Meta, helping to offset its substantial spending on artificial intelligen...

Altisource CEO buys shares amid 19% revenue rise and AI-driven efficiency boost
Altisource Portfolio Solutions' CEO Shepro William B purchased 4,000 shares, increasing his stake to 8,686 shares, signaling confidence in the company's future. The company reported a 19% year-over-year increase in Q2 2026 service revenue to $48.70 m...

Access barriers limit Xphozah uptake despite nephrologists' willingness to triple use, with reimbursement changes ahead.
New research from Spherix Global Insights reveals that access barriers, not drug efficacy, restrict the use of Ardelyx's Xphozah for dialysis patients with hyperphosphatemia. Nephrologists say they would nearly triple Xphozah prescriptions if reimbur...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.